Presbyopia: Emerging Treatments Offer New Hope for the Aging Eye

0.75 CME
0.75 CME WITH ABO CONTINUING CERTIFICATION
45 MINS
$0 FEE
SAVE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Presbyopia: Emerging Treatments Offer New Hope For the Aging Eye

Overview

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education


Support Statement

This activity is supported by an educational grant from AbbVie Inc.


Activity Description

Presbyopia is a universal phenomenon accompanying the aging process. Treatment options for presbyopia are currently limited to corrective lenses or invasive surgical procedures, many of which are not reversible. Patients who require or desire independence from corrective lenses have limited alternative choices. However, pharmacological alternatives are in development and are expected to become available in the near future. These include miotic agents producing a “pinhole effect,” increasing the depth of field, and lens softeners that break disulfide crosslinks, restoring lens flexibility. Ophthalmologists need to be aware of these emerging agents in order to provide their patients with expanded options as they become available. In this CME activity, experts in the field explore the current landscape of medical and surgical therapies for presbyopia as well as the developments in pharmacological treatments for presbyopia to better prepare ophthalmologists to incorporate these treatments into practice once they become available.


Target Audience

The intended audience for this activity is ophthalmologists and other health care professionals involved in the management of patients with presbyopia.


Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Describe the benefits, limitations, and risks of current therapeutic options for the treatment of presbyopia.
  • Evaluate the efficacy and safety of emerging medical approaches for the treatment of presbyopia that may improve outcomes and patient satisfaction.

Activity Chair

Lisa M. Nijm, MD, JD
Founder, MDNegotiation.com
Founder, RealWorldOphthalmology.com
CEO, Women in Ophthalmology
Founder and Medical Director, Warrenville EyeCare and LASIK
Assistant Clinical Professor of Ophthalmology, University of Illinois Eye and Ear Infirmary
Chicago, IL


Faculty

Jennifer M. Loh, MD
Founder, Loh Ophthalmology Associates
Board Member, Eye Physicians of Florida, LLP
Miami, FL


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning and Self-Assessment requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit.

Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn credits equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, October 7, 2021, to October 6, 2022.


How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 of 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.


Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.  

Activity Chair and Faculty report the following relationship(s)

Jennifer M. Loh, MD
Consulting Fee: Allergan, Bausch + Lomb, EyePoint, Eyevance, Imprimis, J&J Vision, Kala, Novartis, Ocular Therapeutix, Omeros, Orasis, Sight Sciences, Sun, Tarsus, Zeiss
Contracted Research: Sight Sciences
Ownership Interest: NovaBay
Speakers Bureau: Aerie, Kala, Sun

Lisa M. Nijm, MD, JD
Consulting Fee: Akorn, Alcon, Allergan (Abbott), Azura, Bausch + Lomb, Bruder, CooperVision, EyePoint, J&J Vision, Kala, Novartis, Ocular Therapeutix, Omeros, Sun, Zeiss
Contracted Research: Ocular Therapeutix
Speakers Bureau: Kala, Omeros, Sun
Medical Advisory Board: LacriScience

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CME Questions?

Contact us at cme@vindicoCME.com